Showing 9,461 - 9,480 results of 18,314 for search 'significantly ((((((nn decrease) OR (largest decrease))) OR (mean decrease))) OR (a decrease))', query time: 0.60s Refine Results
  1. 9461

    Data Sheet 1_Altered gut microbial networks and metabolic pathways in multiple system atrophy: a comparative 16S rRNA study.pdf by Po-Chun Liu (676035)

    Published 2025
    “…Additionally, we identified an increase in the ARGORNPROST-PWY pathway (L-arginine degradation, q = 0.003) and a decrease in the PWY-6478 pathway (GDP-D-glycero-α-D-manno-heptose biosynthesis, q = 0.015) in MSA patients compared with HCs.…”
  2. 9462

    Data Sheet 1_Global, regional, and national burden of pneumococcal disease among children and adolescents aged <20 years from 1990 to 2021: a predictive analysis.docx by Gan-min Wang (21188933)

    Published 2025
    “…Despite a global decrease in burden, significant regional and socioeconomic disparities, as well as long-term trends, are not fully understood.…”
  3. 9463

    Supplementary Material for: Longer term outcomes of laparoscopic peritoneal lavage in the management of acute Hinchey III perforated diverticulitis: A Systematic review and Meta-An... by Sciascia D. (20480867)

    Published 2024
    “…There was significantly decreased likelihood of having a stoma in the LPL group however there was also a significantly increased likelihood of having recurrent diverticulitis. …”
  4. 9464

    Supplementary Material for: The effectiveness of Long-Term Continuation of Atezolizumab Plus Bevacizumab In Patients Who Receiving Systemic Chemotherapy For Advanced Hepatocellular... by figshare admin karger (2628495)

    Published 2025
    “…Results: According to the periods from the initiation of Atez/Bev to that of the second-line therapy, patients were classified into a long continuation group (Group-L, n = 19), ≥ 11 months; or a short continuation group (Group-S, n = 19), < 11 months. …”
  5. 9465

    Variability of gait features during adaptation. by Samantha Jeffcoat (22783930)

    Published 2025
    “…<p>A) We observed significant differences between groups in step length asymmetry variability during EA. …”
  6. 9466

    Table 3_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.docx by Jia-Yi Wang (490704)

    Published 2025
    “…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…”
  7. 9467

    Table 2_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.xlsx by Jia-Yi Wang (490704)

    Published 2025
    “…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…”
  8. 9468

    Table 1_Do the diagnosis-related group payment reforms have a negative impact?—an empirical study from Western China.xlsx by Jia-Yi Wang (490704)

    Published 2025
    “…In the treatment group hospitals, the primary beneficiaries of the reform were urban employees’ basic medical insurance patients, whose costs decreased by 4.9% (p < 0.01), with a non-significant effect on out-of-pocket payment patients and free medical care patients; the hospitals in the treatment group tended to reduce the use of Chinese medicine unique diagnostic and therapeutic means and increase the proportion of western medicine treatments under the pressure of the supremacy of costs.…”
  9. 9469

    Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  10. 9470

    Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  11. 9471

    Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  12. 9472

    Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  13. 9473

    Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

    Published 2025
    “…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”
  14. 9474

    Data Sheet 1_Dupilumab treatment has no effect on the nasal microbiome in patients with NSAID-exacerbated respiratory disease: a longitudinal pilot study.pdf by Tina Bartosik (12300785)

    Published 2025
    “…All 8 patients showed significant reduction in TPS (total polyp score; p=0.0078) and an improvement in SNOT-22 (Sino-nasal outcome test-22, a quality of life questionnaire; p=0.0781) after dupilumab therapy. …”
  15. 9475

    Data Sheet 1_Inflammation mediated brain damage and cytokine expression in a maternally derived murine model for preterm hypoxic-ischemic encephalopathy.pdf by Tyler C. Hillman (13030476)

    Published 2025
    “…MAP2 expression was significantly decreased (p < 0.05) between 1.5–6.0 mm of the brain compared to Saline-Hypoxia and Naïve animals. …”
  16. 9476

    Data Sheet 1_Effect of purpose-directed acupuncture on the pharyngeal phase in stroke patients with dysphagia based on surface electromyography: a randomized controlled trial.pdf by Yan-Qiang Qin (21442067)

    Published 2025
    “…Compared to the control group, the treatment group showed a significant increase in FOIS scores and a decrease in SSA scores. …”
  17. 9477

    Data relevant to the study. by Patcharin Tepjanta (18165111)

    Published 2025
    “…Analysis conducted using the IEDB server indicated that the N320P mutation increased the antigenic index, whereas the N320C mutation significantly decreased it. Conversely, the N320K and N320Q mutations exhibited minor effects on antigenicity. …”
  18. 9478

    Data Sheet 1_MicroRNA-31 mediated inhibition of keratin 6 by PSORI-CM01: a novel approach to psoriasis amelioration.pdf by Shilei Wang (3279066)

    Published 2025
    “…</p>Results<p>In vivo, PSORI-CM01 significantly alleviated the clinical-like manifestations of erythema, scales, and thickening in psoriasis-like mice, and it also reduced the PASI scores; Different concentrations of PSORI-CM01 significantly decreased epidermal thickness and the expression of miR-31 and Krt6 in psoriasis-like mice in a dose-dependent manner. …”
  19. 9479

    S1 File - by Luqiong Liu (11537092)

    Published 2024
    “…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …”
  20. 9480

    Experimental treatments and groups. by Luqiong Liu (11537092)

    Published 2024
    “…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …”